admin
Andrew Engdahl, the current Head of Sales at the digital advertising platform Instapage, has been officially nominated as a candidate for the Leukemia & Lymphoma Society’s (LLS) Visionaries of the Year. This prestigious philanthropic recognition is awarded to community leaders who leverage their professional networks and personal platforms to raise significant funds and awareness for the fight against blood cancers. Engdahl’s nomination follows his personal victory over Stage 4 Non-Hodgkin Lymphoma, a journey that has transitioned him from a critically ill patient to a prominent advocate for cancer research and patient support.
The nomination serves as a milestone in Engdahl’s career and personal life, highlighting the intersection of corporate leadership and humanitarian effort. At Instapage, Engdahl has been instrumental in the company’s commercial scaling, securing several of the organization’s most substantial contracts before ascending to lead the global sales division. His candidacy for Visionaries of the Year is backed by a corporate commitment from Instapage to amplify his message and assist in reaching his ambitious fundraising targets.
A Chronology of Resilience: From Diagnosis to Remission
The narrative of Engdahl’s advocacy began in the summer of 2022. At the time, Engdahl was deeply immersed in his responsibilities at Instapage, initially attributing emerging physical discomfort to simple muscle tension or the rigors of a high-performance professional environment. However, the persistence of these symptoms led to a series of diagnostic tests that revealed a life-altering reality: Stage 4 Non-Hodgkin Lymphoma.
In the medical community, a Stage 4 diagnosis indicates that the cancer has spread outside the lymphatic system to distant organs, such as the liver, lungs, or bone marrow. In Engdahl’s case, the progression necessitated immediate and aggressive intervention. His treatment regimen was multifaceted, involving both high-stakes surgical procedures and systemic therapies.
To address complications arising from the malignancy, Engdahl underwent major spinal surgery. This was followed by a grueling clinical protocol that included four lumbar punctures—a procedure used to check for the spread of cancer to the central nervous system or to deliver chemotherapy directly into the cerebrospinal fluid. Over the ensuing months, he completed six intensive chemotherapy infusions.
Beyond the clinical treatments, Engdahl’s recovery was defined by a rigorous six-month rehabilitation period. This phase focused on physical therapy and yoga, disciplines intended to restore the mobility and strength compromised by both the cancer and the intensive surgical interventions. Today, Engdahl has been in remission for nearly three years, a status that has reframed his professional outlook and personal mission.
Understanding Non-Hodgkin Lymphoma: Data and Context
Non-Hodgkin Lymphoma (NHL) is a primary cancer of the lymphatic system, which is part of the body’s immune system. In NHL, white blood cells called lymphocytes grow abnormally and can form growths (tumors) throughout the body. According to data from the American Cancer Society, NHL is one of the most common cancers in the United States, accounting for about 4% of all cancer diagnoses.
The survival rates for NHL have improved significantly over the last several decades due to advancements in treatment, such as monoclonal antibodies and targeted therapy. For all stages of NHL combined, the five-year relative survival rate is approximately 74%. However, the challenges faced by patients with Stage 4 diagnoses remain substantial, requiring the type of intensive medical and psychological resilience demonstrated by Engdahl.
The Leukemia & Lymphoma Society reports that every three minutes, someone in the United States is diagnosed with a blood cancer. Furthermore, more than 1.6 million people in the U.S. are either living with or are in remission from leukemia, lymphoma, or myeloma. These statistics underscore the critical nature of fundraising initiatives like the Visionaries of the Year campaign, which direct capital toward both cutting-edge research and the immediate financial needs of families navigating a diagnosis.
The Visionaries of the Year Campaign and Fundraising Goals
The Visionaries of the Year campaign (formerly known as Man & Woman of the Year) is a competitive 10-week philanthropic program. Candidates are selected based on their leadership within their communities and their ability to mobilize resources. Engdahl officially launched his campaign on World Cancer Day, a global initiative led by the Union for International Cancer Control (UICC) to raise awareness and encourage prevention, detection, and treatment.
Engdahl has established a personal fundraising goal of $50,000. The funds raised through his campaign page are earmarked for several key areas:
- Research: Funding scientists who are developing the next generation of blood cancer treatments, including immunotherapy and CAR-T cell therapy.
- Patient Support: Providing financial assistance to patients who struggle to afford the rising costs of cancer care, including transportation to treatment centers and co-pay assistance.
- Advocacy: Supporting legislative efforts at the state and federal levels to ensure cancer patients have access to affordable, high-quality care.
In a public statement regarding his candidacy, Engdahl emphasized the concept of "paying it forward." He noted that his survival was made possible by the physicians, researchers, and support systems that preceded him, and he expressed a sense of duty to ensure that future patients have access to the same life-saving opportunities.
Corporate Leadership and the Role of Instapage
The support from Instapage reflects a growing trend of Corporate Social Responsibility (CSR) where companies actively champion the personal causes of their leadership teams. For Instapage, Engdahl’s journey is not merely a personal anecdote but a testament to the culture of resilience the company seeks to foster.
Under Engdahl’s leadership, the sales team has focused on high-growth strategies and client retention. His ability to maintain a high level of professional output while navigating a Stage 4 cancer diagnosis has been cited by colleagues as a source of organizational inspiration. The company has integrated awareness of the campaign into its internal and external communications, viewing Engdahl’s advocacy as an extension of his leadership role.
Industry analysts suggest that leaders who share personal narratives of overcoming adversity can significantly impact company morale and brand perception. By being transparent about his health journey, Engdahl has humanized the leadership of a high-tech firm, potentially fostering deeper connections with both employees and clients.
Broader Implications of Blood Cancer Advocacy
The implications of Engdahl’s campaign extend beyond the $50,000 goal. Philanthropic efforts led by cancer survivors play a crucial role in de-stigmatizing the disease and highlighting the importance of early detection. Engdahl’s initial misinterpretation of his symptoms as "muscle tension" is a common occurrence among cancer patients, and his story serves as a cautionary tale regarding the necessity of medical consultation for persistent physical changes.
Furthermore, the funds raised by LLS candidates have historically led to breakthroughs that benefit patients beyond the scope of blood cancer. Since its founding in 1949, the LLS has invested more than $1.7 billion in research. Many of the treatments originally developed for blood cancer—such as chemotherapy and certain types of immunotherapy—are now standard treatments for many other types of cancer and chronic diseases.
The "Visionaries" program specifically looks for candidates who can act as "pathfinders" in the community. By utilizing his platform as a tech executive, Engdahl is bridging the gap between the corporate sector and the medical research community. This synergy is vital for the continued funding of clinical trials, which often face significant budgetary hurdles.
Conclusion and Future Outlook
As Andrew Engdahl continues his tenure as Head of Sales at Instapage, his focus remains split between driving revenue for the company and driving donations for the Leukemia & Lymphoma Society. His journey from a 2022 diagnosis to a 2025 leadership role in cancer advocacy provides a roadmap for how personal crisis can be transformed into public service.
The 10-week campaign will culminate in a grand finale event where the total funds raised by all candidates will be announced. Regardless of the final ranking, Engdahl’s participation ensures that $50,000—or more—will be funneled into the infrastructure required to defeat blood cancer. For Engdahl, the campaign is a fulfillment of a promise made during his darkest days of treatment: to use his "second chance" to clear the path for those who follow.
The tech community and the broader public are encouraged to follow Engdahl’s progress and contribute to the mission. As research continues to evolve and survival rates continue to climb, the efforts of individual "visionaries" like Engdahl remain the backbone of the global movement to eradicate cancer.
